Intuitive Surgical Ends 2025 Strong with Robot Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 31 2026
0mins
Should l Buy ISRG?
Source: Fool
- Robot Sales Growth: In Q4 2025, Intuitive Surgical successfully deployed 532 da Vinci surgical robots, an 8% increase from 493 in Q4 2024, indicating strong demand and an expanding market share in surgical robotics.
- Revenue Structure Analysis: While surgical robot sales accounted for about 25% of total revenue in 2025, instruments and accessories made up a substantial 60%, highlighting the company's diversified revenue streams and robust profitability in the medical device sector.
- Recurring Revenue Model: Approximately 75% of revenue is recurring, growing with each new da Vinci system installed, which underscores the company's strong potential in maintenance and parts sales, further solidifying its market position.
- AI Integration Opportunities: The FDA-approved AI tool received in late 2025 will provide real-time visual enhancements for lung biopsy surgeries, representing a small yet significant step that showcases Intuitive Surgical's innovative capabilities and future growth potential in surgical robotics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 479.930
Low
575.00
Averages
637.32
High
740.00
Current: 479.930
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Intuitive Surgical Issues Safety Alert for da Vinci System Defect
- Safety Alert Issued: The FDA announced that Intuitive Surgical has issued a safety alert regarding defects in its da Vinci surgical system, specifically related to the 8mm SureForm 30 Gray Reload devices, which can lead to incomplete staple line formation in blood vessels, potentially causing severe bleeding that may necessitate conversion to open surgery, thereby impacting patient safety.
- Customer Notification Actions: On March 11, Intuitive Surgical notified affected customers to cease using the product and seek alternatives, demonstrating the company's commitment to customer safety, yet this may adversely affect its market reputation.
- Incident Reporting Status: As of February 23, the FDA has recorded four serious injuries and one death associated with the defect, highlighting the potential risks of the product, which may expose the company to legal and financial liabilities.
- Market Reaction: Following the FDA alert, Intuitive Surgical's shares slipped in morning trading on Wednesday, reflecting investor concerns regarding the safety of the company's products, which could impact its future market performance and growth expectations.
See More
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
Intuitive Surgical's Financial Outlook Ahead of Earnings Release
- Stock Performance: Intuitive Surgical, Inc. closed at $472.16, reflecting a 1.48% decline from the previous day, yet it has gained 0.14% over the past month, outperforming the Medical sector's 4.48% loss, indicating relative resilience.
- Financial Expectations: The upcoming earnings report is projected to show an EPS of $2.08, a 14.92% increase year-over-year, with revenue expected at $2.61 billion, up 15.86% from the prior year, highlighting the company's strong market performance and profit potential.
- Analyst Confidence: The Zacks Consensus Estimates suggest analysts expect full-year earnings of $10.06 per share and revenue of $11.56 billion, representing increases of 12.65% and 14.86% respectively from last year, reflecting confidence in the company's future performance.
- Valuation Analysis: Intuitive Surgical currently trades at a forward P/E ratio of 47.62, significantly above the industry average of 20.03, while its PEG ratio stands at 3.03, indicating market expectations for future growth, with the company ranked in the top 37% of the Medical Instruments industry.
See More
Intuitive Surgical Faces Cybersecurity Incident Impacting IT Applications
- Cybersecurity Incident: Intuitive Surgical (ISRG) reported a targeted phishing incident that allowed unauthorized access to certain internal IT business applications, causing its shares to drop to session lows on Friday, highlighting the direct impact of cybersecurity risks on stock performance.
- Product Safety Assurance: The company reassured stakeholders that its products, including the da Vinci surgical system, Ion, and digital platforms, remain safe and operational, indicating effective crisis management that helps maintain customer trust during challenging times.
- Industry Impact: Intuitive Surgical is the second U.S. MedTech firm to experience a system breach this week, following Stryker (SYK), which faced a cyberattack that disrupted its Microsoft (MSFT)-based systems, reflecting the widespread cybersecurity threats facing the industry and potentially affecting investor confidence.
- Future Growth Outlook: Despite the cybersecurity challenges, Intuitive Surgical anticipates a 13-15% growth rate in da Vinci procedures by 2026, demonstrating strong growth potential in global expansion that may attract long-term investor interest.
See More
Intuitive Surgical Reports Strong 2025 Results but Faces High Valuation Risks
- Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, while full-year revenue rose 21% to $10.1 billion, indicating strong demand and market acceptance for its robotic-assisted surgical systems.
- Surgical Volume Continues to Rise: The company experienced an approximately 18% year-over-year growth in global procedure volume in Q4, installing 532 da Vinci surgical systems during the quarter compared to 493 a year ago, pushing its global installed base to over 11,100 systems, further solidifying its market leadership.
- Decelerating Growth Outlook: Management expects da Vinci procedures to grow by 13% to 15% in 2026, a notable slowdown from the 18% growth achieved in 2025, reflecting a cautious market sentiment that could impact investor confidence moving forward.
- High Valuation Risks: With a market capitalization of about $175 billion and a price-to-earnings ratio of approximately 63, Intuitive Surgical's high valuation poses significant risks, especially as the company faces a deceleration in growth, which could pressure its stock price even if operational performance remains strong.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Intuitive Surgical Issues Safety Alert for da Vinci System Defect
- Safety Alert Issued: The FDA announced that Intuitive Surgical has issued a safety alert regarding defects in its da Vinci surgical system, specifically related to the 8mm SureForm 30 Gray Reload devices, which can lead to incomplete staple line formation in blood vessels, potentially causing severe bleeding that may necessitate conversion to open surgery, thereby impacting patient safety.
- Customer Notification Actions: On March 11, Intuitive Surgical notified affected customers to cease using the product and seek alternatives, demonstrating the company's commitment to customer safety, yet this may adversely affect its market reputation.
- Incident Reporting Status: As of February 23, the FDA has recorded four serious injuries and one death associated with the defect, highlighting the potential risks of the product, which may expose the company to legal and financial liabilities.
- Market Reaction: Following the FDA alert, Intuitive Surgical's shares slipped in morning trading on Wednesday, reflecting investor concerns regarding the safety of the company's products, which could impact its future market performance and growth expectations.
See More
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
Intuitive Surgical's Financial Outlook Ahead of Earnings Release
- Stock Performance: Intuitive Surgical, Inc. closed at $472.16, reflecting a 1.48% decline from the previous day, yet it has gained 0.14% over the past month, outperforming the Medical sector's 4.48% loss, indicating relative resilience.
- Financial Expectations: The upcoming earnings report is projected to show an EPS of $2.08, a 14.92% increase year-over-year, with revenue expected at $2.61 billion, up 15.86% from the prior year, highlighting the company's strong market performance and profit potential.
- Analyst Confidence: The Zacks Consensus Estimates suggest analysts expect full-year earnings of $10.06 per share and revenue of $11.56 billion, representing increases of 12.65% and 14.86% respectively from last year, reflecting confidence in the company's future performance.
- Valuation Analysis: Intuitive Surgical currently trades at a forward P/E ratio of 47.62, significantly above the industry average of 20.03, while its PEG ratio stands at 3.03, indicating market expectations for future growth, with the company ranked in the top 37% of the Medical Instruments industry.
See More
Intuitive Surgical Faces Cybersecurity Incident Impacting IT Applications
- Cybersecurity Incident: Intuitive Surgical (ISRG) reported a targeted phishing incident that allowed unauthorized access to certain internal IT business applications, causing its shares to drop to session lows on Friday, highlighting the direct impact of cybersecurity risks on stock performance.
- Product Safety Assurance: The company reassured stakeholders that its products, including the da Vinci surgical system, Ion, and digital platforms, remain safe and operational, indicating effective crisis management that helps maintain customer trust during challenging times.
- Industry Impact: Intuitive Surgical is the second U.S. MedTech firm to experience a system breach this week, following Stryker (SYK), which faced a cyberattack that disrupted its Microsoft (MSFT)-based systems, reflecting the widespread cybersecurity threats facing the industry and potentially affecting investor confidence.
- Future Growth Outlook: Despite the cybersecurity challenges, Intuitive Surgical anticipates a 13-15% growth rate in da Vinci procedures by 2026, demonstrating strong growth potential in global expansion that may attract long-term investor interest.
See More
Intuitive Surgical Reports Strong 2025 Results but Faces High Valuation Risks
- Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, while full-year revenue rose 21% to $10.1 billion, indicating strong demand and market acceptance for its robotic-assisted surgical systems.
- Surgical Volume Continues to Rise: The company experienced an approximately 18% year-over-year growth in global procedure volume in Q4, installing 532 da Vinci surgical systems during the quarter compared to 493 a year ago, pushing its global installed base to over 11,100 systems, further solidifying its market leadership.
- Decelerating Growth Outlook: Management expects da Vinci procedures to grow by 13% to 15% in 2026, a notable slowdown from the 18% growth achieved in 2025, reflecting a cautious market sentiment that could impact investor confidence moving forward.
- High Valuation Risks: With a market capitalization of about $175 billion and a price-to-earnings ratio of approximately 63, Intuitive Surgical's high valuation poses significant risks, especially as the company faces a deceleration in growth, which could pressure its stock price even if operational performance remains strong.
See More
